Diferencia entre revisiones de «Template:Cholecystitis Antibiotics»
Sin resumen de edición |
Sin resumen de edición |
||
| Línea 2: | Línea 2: | ||
====Uncomplicated==== | ====Uncomplicated==== | ||
''Pathogenicity of [[Enterococci]] remains unclear and specific coverage is not routinely suggested for community-acquired infections''<ref>Ansaloni L, et al. 2016 WSES guidelines on acute calculous cholecystitis. World Journal of Surgery. (2016) 11:25. DOI 10.1186/s13017-016-0082-5</ref> | ''Pathogenicity of [[Enterococci]] remains unclear and specific coverage is not routinely suggested for community-acquired infections''<ref name=“WSES 2016”>Ansaloni L, et al. 2016 WSES guidelines on acute calculous cholecystitis. World Journal of Surgery. (2016) 11:25. DOI 10.1186/s13017-016-0082-5</ref> | ||
*[[Ertapenem]] 1g IV once daily OR | *[[Ertapenem]] 1g IV once daily OR | ||
*[[Metronidazole]] 500mg IV q8hrs PLUS | *[[Metronidazole]] 500mg IV q8hrs PLUS | ||
Revisión del 03:56 3 abr 2019
Most often isolated organisms are Escherichia coli, Klebsiella pneumonia, and anaerobes, especially Bacteroides fragilis
Uncomplicated
Pathogenicity of Enterococci remains unclear and specific coverage is not routinely suggested for community-acquired infections[1]
- Ertapenem 1g IV once daily OR
- Metronidazole 500mg IV q8hrs PLUS
- Ciprofloxacin 400mg IV q12 hrs OR
- Levofloxacin 750mg IV q24hrs OR
- Ceftriaxone 1g IV q24hrs
Complicated or Healthcare Associated
Examples of complication include severe sepsis or hemodynamic instability
- Vancomycin 15-20mg/kg PLUS any of the following options
Options:
- Metronidazole 500mg IV q8hrs PLUS Ciprofloxacin 400mg IV q12hrs
- Piperacillin/Tazobactam 4.5g IV q8hrs
- Imipenem/Cilastin 500mg IV q6hrs
- Doripenem 500mg IV q8hrs
- Meropenem 1g IV q8hrs
- ↑ Ansaloni L, et al. 2016 WSES guidelines on acute calculous cholecystitis. World Journal of Surgery. (2016) 11:25. DOI 10.1186/s13017-016-0082-5